$XBI $136 +1.0%
Covid Updates
$MRNA -0.2% Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States. source
$OCGN -28.1% Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate. source
$BNTX -0.7% & PFE +2.2% Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations. source
Pipeline Updates
$HRMY -0.4% Harmony Biosciences Presents New Analysis Demonstrating The Clinical Impact Of WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting. source
$TMDX +1.1% TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting. source
$ADMS +5.8% New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease. source
$IBRX -3.1% ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients. source
$VERU -1.3% Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer. source
$ETNB +1.4% 89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH. source
$CASI +0.6% CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma. source
$CUE +3.5% Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC. source
$VOR +6.8% Vor to Develop Multi-Targeted CAR-Ts with Abound Bio. source
$EQ -2.0% Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry. source
$OYST +2.0% Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases. source
$ALXO +1.8% ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer. source
$GKOS 0% Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR. source
$MNKD -1.2% MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases. source
$OBSV +4.3% ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021. source
$INRLF +0.9% Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate. source
$MDWD +14.3% MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study. source4
$PRTA +14.3% Prothena to Participate in JMP Securities Life Sciences Conference on June 16. source
$ANVS +12.1% On 6/8 Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study. source4htbx
$HTBX +40.2% HS-110 favorable survival data reported at ASCO2021. source
Financial Updates
$VRNA +13.2% Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China. source
$ORPH +302.3% Orphazyme and CytRx skyrocket ahead of FDA decision on Arimoclomol. source
$CYTR +55.0% Orphazyme and CytRx skyrocket ahead of FDA decision on Arimoclomol. source
$HEPA +15.3% Hepion Pharmaceuticals to be Added to the Russell Microcap® Index. source
$AXLA +48.7% AXA1125 trial initiating in June. source
$GLTO +60% Galecto Hosted Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments on 6/9/21. source
Posted by FS